Q2 2013 Earnings Call (Transcript)

Quote

quickann

Guest
Source:
http://www.earningsimpact.com/Transcript/82284/LLY/Q2-2013-Earnings-Call

Some extracts from the transcript:

"In Europe the volume decline of 4% was due to the Zyprexa patent expiration and transfer of exenatide commercial rights outside of the U.S. to Amylin Pharmaceuticals. Excluding Zyprexa and exenatide from both 2012 and 2013 volumes for the rest of our European products was up almost 3%.

Turning to Japan our revenues were once again significantly impacted by the weakening of the yen. The 18% decline from foreign exchange and 3% price decline were partially offset by strong double-digit volume growth of 10%. Volume growth was primarily driven by Forteo, Strattera, Tradjenta and Evista."
 




"We cooked the books just enough to inflate the stock price so that some senior staff can depart during rosy company performance later this year with a fully inflated golden parachute"
 




That was an old lesson learn from the Dick Wood days. That why under his great leadership Lilly had 31 quarters of profit growth earning. So just new dog learning old tricks with the books. Things never change on b74 12 floor. Must some code book left there that only the CEO can read.
 








Anonymous said:
You mean Ken Lay?
Click to expand...

Nah Ken was just on the BOD so he could get the computer contract for Compaq. If Ken would have been involved we'd been exposed years ago.

Ken's methodology is something that small biotechs still use today ... promising products that never made it to market and keep selling stock and giving $0 shares to the CEO.
 












Top Bottom
Back
Quote